1. Home
  2. SGHT vs STXS Comparison

SGHT vs STXS Comparison

Compare SGHT & STXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SGHT
  • STXS
  • Stock Information
  • Founded
  • SGHT 2011
  • STXS 1990
  • Country
  • SGHT United States
  • STXS United States
  • Employees
  • SGHT N/A
  • STXS N/A
  • Industry
  • SGHT Medical Specialities
  • STXS Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • Sector
  • SGHT Health Care
  • STXS Health Care
  • Exchange
  • SGHT Nasdaq
  • STXS Nasdaq
  • Market Cap
  • SGHT 140.1M
  • STXS 151.3M
  • IPO Year
  • SGHT 2021
  • STXS 2004
  • Fundamental
  • Price
  • SGHT $3.22
  • STXS $1.98
  • Analyst Decision
  • SGHT Buy
  • STXS
  • Analyst Count
  • SGHT 7
  • STXS 0
  • Target Price
  • SGHT $3.83
  • STXS N/A
  • AVG Volume (30 Days)
  • SGHT 189.8K
  • STXS 422.2K
  • Earning Date
  • SGHT 05-08-2025
  • STXS 05-12-2025
  • Dividend Yield
  • SGHT N/A
  • STXS N/A
  • EPS Growth
  • SGHT N/A
  • STXS N/A
  • EPS
  • SGHT N/A
  • STXS N/A
  • Revenue
  • SGHT $79,866,000.00
  • STXS $26,918,000.00
  • Revenue This Year
  • SGHT N/A
  • STXS $34.90
  • Revenue Next Year
  • SGHT $11.17
  • STXS $58.64
  • P/E Ratio
  • SGHT N/A
  • STXS N/A
  • Revenue Growth
  • SGHT N/A
  • STXS 0.55
  • 52 Week Low
  • SGHT $2.03
  • STXS $1.54
  • 52 Week High
  • SGHT $8.45
  • STXS $2.72
  • Technical
  • Relative Strength Index (RSI)
  • SGHT 67.25
  • STXS 56.75
  • Support Level
  • SGHT $2.40
  • STXS $1.78
  • Resistance Level
  • SGHT $3.44
  • STXS $2.07
  • Average True Range (ATR)
  • SGHT 0.28
  • STXS 0.13
  • MACD
  • SGHT 0.11
  • STXS 0.04
  • Stochastic Oscillator
  • SGHT 84.40
  • STXS 82.08

About SGHT Sight Sciences Inc.

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.

About STXS Stereotaxis Inc.

Stereotaxis Inc is engaged in robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. The company's mission is the discovery, development, and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. The company's revenue generation is derived from the streams of Systems; Disposables, Royalty; and Sublease, of which a majority of revenue is generated from the Disposables, service, and accessories stream.

Share on Social Networks: